Your browser is no longer supported. Please, upgrade your browser.
Laboratory Corporation of America Holdings
IndexS&P 500 P/E9.60 EPS (ttm)29.29 Insider Own0.59% Shs Outstand97.40M Perf Week2.47%
Market Cap26.87B Forward P/E17.11 EPS next Y16.43 Insider Trans-2.45% Shs Float95.83M Perf Month-5.16%
Income2.88B PEG- EPS next Q4.92 Inst Own93.10% Short Float1.85% Perf Quarter-0.73%
Sales16.39B P/S1.64 EPS this Y90.00% Inst Trans0.27% Short Ratio2.96 Perf Half Y6.40%
Book/sh105.19 P/B2.67 EPS next Y-32.00% ROA14.50% Target Price334.29 Perf Year35.46%
Cash/sh20.54 P/C13.69 EPS next 5Y-9.75% ROE30.40% 52W Range192.79 - 309.60 Perf YTD38.08%
Dividend- P/FCF9.47 EPS past 5Y29.60% ROI12.10% 52W High-9.22% Beta1.01
Dividend %- Quick Ratio2.00 Sales past 5Y10.00% Gross Margin38.60% 52W Low45.79% ATR5.29
Employees72400 Current Ratio2.10 Sales Q/Q38.70% Oper. Margin25.00% RSI (14)48.21 Volatility1.66% 1.87%
OptionableYes Debt/Eq0.54 EPS Q/Q100.80% Profit Margin17.60% Rel Volume0.97 Prev Close282.15
ShortableYes LT Debt/Eq0.54 EarningsOct 28 BMO Payout0.00% Avg Volume599.45K Price281.07
Recom1.70 SMA201.00% SMA50-3.75% SMA2005.45% Volume581,794 Change-0.38%
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-15-20Upgrade Mizuho Neutral → Buy $158 → $186
Apr-29-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-27-20Upgrade Citigroup Neutral → Buy $204 → $214
Jan-08-20Initiated Wells Fargo Overweight $210
Jul-16-19Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19Upgrade Deutsche Bank Hold → Buy $180 → $220
Apr-02-19Upgrade Jefferies Hold → Buy $154 → $190
Jan-17-19Initiated UBS Buy $169
Jan-03-19Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18Downgrade Craig Hallum Buy → Hold
Oct-30-18Downgrade Argus Buy → Hold
Oct-25-18Downgrade Canaccord Genuity Buy → Hold $190 → $162
Oct-19-18Resumed BofA/Merrill Buy
Oct-22-21 11:03AM  
Oct-21-21 03:02PM  
Oct-20-21 11:50AM  
Oct-19-21 12:10PM  
Oct-15-21 09:10AM  
Oct-14-21 10:00AM  
Oct-13-21 07:14AM  
Oct-08-21 07:43AM  
Oct-06-21 11:50AM  
Oct-04-21 12:11PM  
Oct-01-21 11:49AM  
Sep-28-21 04:18PM  
Sep-27-21 08:30AM  
Sep-14-21 10:26AM  
Sep-13-21 04:35PM  
Sep-10-21 09:28AM  
Sep-08-21 04:12PM  
Sep-02-21 06:38PM  
Aug-30-21 11:57AM  
Aug-23-21 12:59PM  
Aug-20-21 09:27AM  
Aug-19-21 04:37PM  
Aug-13-21 02:10PM  
Aug-12-21 04:19PM  
Jul-31-21 10:07AM  
Jul-30-21 12:49PM  
Jul-29-21 03:00PM  
Jul-28-21 01:18PM  
Jul-26-21 09:15AM  
Jul-23-21 12:10PM  
Jul-22-21 03:03PM  
Jul-21-21 07:35AM  
Jul-20-21 06:59AM  
Jul-19-21 08:50AM  
Jul-16-21 11:50AM  
Jul-15-21 08:27AM  
Jul-14-21 07:51AM  
Jul-12-21 08:15AM  
Jul-08-21 09:15AM  
Jul-05-21 07:51AM  
Jul-02-21 06:59AM  
Jul-01-21 05:03PM  
Jun-30-21 11:50AM  
Jun-28-21 11:30AM  
Jun-26-21 07:36AM  
Jun-24-21 10:28AM  
Jun-23-21 04:40PM  
Jun-22-21 08:28AM  
Jun-18-21 06:20AM  
Jun-16-21 04:42PM  
Jun-15-21 07:32AM  
Jun-14-21 11:11AM  
Jun-09-21 11:47AM  
Jun-08-21 04:35PM  
Jun-03-21 07:14PM  
Jun-02-21 05:20PM  
May-31-21 03:30AM  
May-28-21 09:10AM  
May-25-21 03:56PM  
May-24-21 05:14PM  
May-21-21 06:10PM  
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Vaart Sandra DEVP, Chief Legal OfficerSep 15Option Exercise84.864,500381,8709,765Sep 17 12:20 PM
van der Vaart Sandra DEVP, Chief Legal OfficerSep 15Sale296.784,5001,335,5105,265Sep 17 12:20 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Option Exercise84.864,500381,8709,737Jun 09 02:03 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Sale266.564,5001,199,5205,237Jun 09 02:03 PM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 06Sale276.552,500691,3757,844May 10 08:21 AM
BELINGARD JEAN-LUCDirectorMay 03Option Exercise98.492,600256,07418,169May 05 10:48 AM
BELINGARD JEAN-LUCDirectorMay 03Sale269.162,600699,80315,569May 05 10:48 AM
van der Vaart Sandra DEVP, Chief Legal OfficerMar 30Sale251.88812204,5275,237Apr 01 08:32 AM
Schroeder Mark SEVP, President-Diagnostics LabMar 30Sale251.88667168,0045,006Apr 01 08:32 AM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Option Exercise157.092,166340,2512,660Feb 19 02:17 PM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Sale241.512,317559,589343Feb 19 02:17 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 16Sale236.5520849,2024,426Feb 17 04:28 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 16Sale237.0618844,5674,339Feb 17 04:27 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05Sale225.8510924,6184,219Feb 08 03:43 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 05Sale225.8520345,8484,152Feb 08 03:40 PM
Williams R SandersDirectorJan 26Option Exercise98.491,300128,0375,246Jan 28 12:11 PM
Schroeder Mark SEVP, President-Diagnostics LabNov 06Sale214.59588126,1793,949Nov 10 10:48 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentNov 04Sale214.141,500321,2047,698Nov 06 09:06 AM